SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; SyB L-1702, an RI administration under the TREAKISYM name; … Read more
SymBio Pharmaceuticals Limited (SYMQY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 0.007x
Based on the latest financial reports, SymBio Pharmaceuticals Limited (SYMQY) has a cash flow conversion efficiency ratio of 0.007x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($47.67 Million) by net assets ($7.21 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SymBio Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how SymBio Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SymBio Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SymBio Pharmaceuticals Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Installux
PA:ALLUX
|
0.039x |
|
352090
KQ:352090
|
0.051x |
|
M2i Global Inc.
OTCQB:MTWO
|
0.262x |
|
SCHMID Group N.V. Warrants
NASDAQ:SHMDW
|
N/A |
|
Santacruz Silver Mining Ltd.
OTCQB:SCZMF
|
0.125x |
|
TIER 1 TECHNOLOGY EO-01
F:V78
|
N/A |
|
Asian Insulators PCL
BK:AI
|
0.030x |
|
Calgro M3 Holdings Limited
PINK:CLMHF
|
0.031x |
Annual Cash Flow Conversion Efficiency for SymBio Pharmaceuticals Limited (2008–2025)
The table below shows the annual cash flow conversion efficiency of SymBio Pharmaceuticals Limited from 2008 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.27 Billion | $-4.80 Billion | -3.769x | -363.04% |
| 2024-12-31 | $4.20 Billion | $-3.42 Billion | -0.814x | -2914.28% |
| 2023-12-31 | $7.21 Billion | $-194.69 Million | -0.027x | -114.23% |
| 2022-12-31 | $8.51 Billion | $1.61 Billion | 0.190x | +814.12% |
| 2021-12-31 | $6.75 Billion | $140.04 Million | 0.021x | +102.35% |
| 2020-12-31 | $4.66 Billion | $-4.12 Billion | -0.885x | +10.48% |
| 2019-12-31 | $4.40 Billion | $-4.35 Billion | -0.989x | -108.50% |
| 2018-12-31 | $4.90 Billion | $-2.32 Billion | -0.474x | +59.75% |
| 2017-12-31 | $3.24 Billion | $-3.82 Billion | -1.178x | -229.70% |
| 2016-12-31 | $5.48 Billion | $-1.96 Billion | -0.357x | +30.28% |
| 2015-12-31 | $4.43 Billion | $-2.27 Billion | -0.513x | -181.91% |
| 2014-12-31 | $6.96 Billion | $-1.27 Billion | -0.182x | +19.42% |
| 2013-12-31 | $7.43 Billion | $-1.68 Billion | -0.226x | +33.33% |
| 2012-12-31 | $4.90 Billion | $-1.66 Billion | -0.338x | -7.80% |
| 2011-12-31 | $6.61 Billion | $-2.07 Billion | -0.314x | -70.04% |
| 2010-12-31 | $4.08 Billion | $-753.97 Million | -0.185x | -254.20% |
| 2009-12-31 | $4.05 Billion | $-211.34 Million | -0.052x | -144.12% |
| 2008-12-31 | $1.31 Billion | $154.39 Million | 0.118x | -- |